Seeking Alpha

Leerink talks AstraZeneca, Clovis, and NSCLC

  • AstraZeneca's (AZN +0.1%) AZD9291 and Clovis Oncology's (CLVS -0.9%) CO-1686 have "blockbuster potential," Leerink's Seamus Fernandez thinks, after considering AZN's ESMO showing. (previous coverage)
  • The partial responses in patients with the T790M mutation and "excellent overall tolerability" make Fernandez comfortable with adding $500M to Leerink's AZD-9291 model.
  • CLVS is maintained at Outperform with an $88 price target — apparently, there's room for two in the market.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs